News
Partners Summit Therapeutics and Akeso are expected to steal the show at the American Society of Clinical Oncology’s annual conference with data from their potential Keytruda rival, alongside Revolution Medicine’s groundbreaking pancreatic cancer candidate and other assets that could reshape patient care.
FEATURED STORIES
While the pathogen appears unlikely to trigger a pandemic, analysts see potential for Moderna to build goodwill amid a period of political pressure on vaccine manufacturers.
Clinical trial setbacks have limited the near-term opportunities for some of Daiichi Sankyo’s ADCs but the drug developer is betting near-term readouts will catapult it into the top tier of oncology companies in the coming years.
BioSpace analyzed the pay ratio across 10 major pharmaceutical companies to determine which CEOs were paid the most relative to typical employees. J&J, Eli Lilly and Pfizer once again topped the list.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
The Department of Health and Human Services is spinning its wheels, unable to establish steady leadership at three major divisions—the CDC and the FDA’s two primary review units.
THE LATEST
Not surprisingly, the week between Christmas and New Year was quiet in terms of clinical trial news. However, there were some announcements. Here’s a look.
Korea Economic Daily, published a story saying that Samsung Group was in talks to acquire Biogen. However, Samsung BioLogics stated in a regulatory filing yesterday that the rumor is not true.
Janssen Pharmaceutical has recently applied for Biologics License Application for its relapsed or refractory (r/r) multiple myeloma drug. Here’s all about it.
The two companies are already looking at the coming year and seeing the potential for their experimental treatment ofATTR, Eplontersen, formerly known as IONIS-TTR-L.
Part of what is being discovered about the Omicron variant of COVID-19 is how fast it appears to infect people, a median of about three days, compared to four or five with other variants.
Not surprisingly, there’s still plenty of interesting research coming out about COVID-19, but the end of 2021 also provided exciting science in other areas. Here’s a look.
Collegium reached a $2.75 million agreement with a law firm representing 27 U.S. cities, counties and subdivisions related to the opioid crisis and the company’s sale of Xtampza.
The decision to allow the release of Adbry follows positive results from the Phase III ECZTRA trials, which covered almost 2,000 patients living with moderate to severe atopic dermatitis.
BridgeBio Pharma reported topline data from Part A (Month 12) of its Phase III study of acoramidis for symptomatic transthyretin amyloid cardiomyopathy. The drug failed the study arm.
The company was assessing mavrilimumab as a potential therapeutic for COVID-19-related acute respiratory syndrome.